– IRELAND, Belfast – Fusion Antibodies plc (LON: FAB), specialists in pre-clinical antibody discovery, engineering, and supply for both therapeutic drug and diagnostic applications, today announced the appointment of Dr. Adrian Kinkaid (Ph.D.) as CEO, effective from Monday 15 August 2022.
“I would like to welcome Adrian who joins Fusion at an exciting time as we focus on growing our antibody services and completing the development of and commercial roll out next year of OptiMAL, our Mammalian Antibody library.” said Board Chairman, Simon Douglas.
About Dr. Adrian Kinkaid
Adrian Kinkaid is an experienced life sciences executive with 25 years of experience in the life science and biotherapeutics industries. He joins Fusion from Vortex Liquid Biopsy Solutions Ltd and Vortex Biosciences Inc., a biotech group focused on world-class technology for the isolation of high-quality circulating tumor cells. As CEO of Vortex, Adrian led the company’s development, including the management of its business units.
Before joining Vortex, Adrian worked as CEO at several antibody-based diagnostics companies including BioFab Ltd, and Lumabs BV. He was formerly CCO for Promexus Ltd, a protein biotherapeutics company where he developed the corporate strategy for Therapeutic Affimers, culminating in a multi-target deal with a potential of over $1bn. Adrian was previously CBO of the Aptamer Group, and Strategic Market Development Leader for Abcam plc, the leading provider of research antibodies.
Dr. Adrian Kinkaid has a Ph.D. in Biochemistry and undertook postdoctoral research with the Institute of Cancer Research, London. As Chairman and founding member of the European Laboratory Research and Innovation Group, Adrian established their flagship Drug Discovery event, which is now the leading conference of its kind in Europe.
Dr. Kinkaid said: “I am delighted to be joining Fusion Antibodies at this exciting time of growth and look forward to leading the Company to further commercial success. Fusion Antibodies has a world-class technology platform built over the last decade that has the potential to generate significant value and play a global role in the provision of high-quality services to enhance the discovery and development of novel, effective antibody therapeutics.”
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification, and sequencing, antibody humanization using Fusion’s proprietary CDRxTM platform, and cell line development, producing antibody-generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and completed over 200 humanization projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client’s vision is central to how we work in combining the latest technological advances with cutting-edge science. In this work, our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation to ensure the best molecule goes to the clinic. Fusion Antibodies’ growth strategy is based on enabling Pharma and Biotech companies to get to the clinic more effectively, using molecules with optimized therapeutic profiles and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion’s use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,
Fusion Antibodies’ emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.
For more information: https://www.fusionantibodies.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
